Rigshospitalet Copenhagen is now our clinical partner

The study is designed as follows:
Pilot study
Inclusion of 10-15 healthy children and children with known visual field defects (ages 4-12) to test the setup of the equipm
ent and the possibility of detection of visual field defect. The children will also go through some basic ophthalmological exams (VA, OCT, SAP ect).

Study 1:
Inclusion of 50 healthy children in the ages 4-12. The aim is to test the feasibility of using the device in pediatric population. The children will also go through some basic ophthalmological exams (VA, OCT, SAP ect).

Study 2:
Inclusion of 50 children with known visual field defects (ocular and neurological pathologies) in the ages 4-12. The aim is to test the feasibility of the device in children with VFDs and other possibly cognitive/neurological impairments and to validate the ability to detect VFDs in this population. Bulbicam will be compared with other methods chosen based on the childs age and cognitive ability (Goldmann, SAP, Campimetry, confrontation).

Study 3:
Inclusion of children ages 4-17 with newly diagnosed intracranial CNS tumors in Denmark. The aim is to examine and compare methods for visual field examination in these children and look at other aspects of vision such as contrast sensitivity and oculomotor behavior in general.